Bränström R, et al. - Linking the Swedish Total Population Register (N = 9,747,324) to the National Patient Register and the Prescribed Drug Register, researchers investigated the entire Swedish population for the prevalence of mood and anxiety disorder healthcare visits and antidepressant and anxiolytic prescriptions in 2015 as a function of gender incongruence diagnosis and gender-affirming hormone and surgical treatment. Compared with the general population, individuals with a gender incongruence diagnosis were noted to have approximately six times higher tendency to have had a mood and anxiety disorder healthcare visit, more than three times higher likelihood to have received prescriptions for antidepressants and anxiolytics, and more than six times higher likelihood to have been hospitalized after a suicide attempt. These findings support the decision to implement gender-affirming surgeries to transgender individuals who seek them.